{"title": "New study offers hope for patients suffering from a rare form of blindness", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/gene_therapy.xml", "value": "New study offers hope for patients suffering from a rare form of blindness"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2018/11/181101142900.htm"}], "link": "https://www.sciencedaily.com/releases/2018/11/181101142900.htm", "summary": "A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness. This hyper-targeted approach offers hope to individuals living with spinocerebellar ataxia type 7 (SCA7) and validates a new form of therapy with the potential to treat neurogenetic diseases effectively and with far fewer side effects than other medications.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/gene_therapy.xml", "value": "A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness. This hyper-targeted approach offers hope to individuals living with spinocerebellar ataxia type 7 (SCA7) and validates a new form of therapy with the potential to treat neurogenetic diseases effectively and with far fewer side effects than other medications."}, "published": "Thu, 01 Nov 2018 14:29:00 EDT", "published_parsed": [2018, 11, 1, 18, 29, 0, 3, 305, 0], "id": "https://www.sciencedaily.com/releases/2018/11/181101142900.htm", "guidislink": false}